CONSOLIDATED BALANCE SHEETS (USD $) In Thousands, unless otherwise specified	Dec. 31, 2014	Dec. 31, 2013
Current assets:
Cash and cash equivalents	$ 648,719	$ 535,608
Marketable securities	251,761	158,376
Accounts receivable - trade, net	739,379	787,071
Accounts receivable from Sanofi	121,058	104,707
Accounts receivable from Bayer HealthCare	156,962	63,189
Inventories	128,861	70,354
Deferred tax assets	49,235	44,677
Prepaid expenses and other current assets	71,486	32,952
Total current assets	2,167,461	1,796,934
Marketable securities	460,154	389,891
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	974,309	526,983
Deferred tax assets	266,869	231,878
Other assets	3,034	5,327
Total assets	3,871,827	2,951,013
Current liabilities:
Accounts payable and accrued expenses	484,228	250,896
Deferred revenue from Sanofi, current portion	15,927	12,815
Deferred revenue - other, current portion	58,098	34,185
Other current liabilities	96,407	939
Total current liabilities	654,660	298,835
Deferred revenue from Sanofi	72,367	76,522
Deferred revenue - other	103,909	107,677
Facility lease obligations	310,938	184,258
Convertible senior notes	146,773	320,315
Other long term liabilities	40,855	11,330
Total liabilities	1,329,502	998,937
Commitments and contingencies (Note 13)
Stockholders' equity:
Preferred Stock	0	0
Additional paid-in capital	2,404,118	2,045,857
Retained earnings (accumulated deficit)	255,382	(92,692)
Accumulated other comprehensive income (loss)	52,251	(1,188)
Treasury Stock, Value	(169,530)	0
Total stockholders' equity	2,542,325	1,952,076
Total liabilities and stockholders' equity	3,871,827	2,951,013
Class A Stock
Stockholders' equity:
Common stock	2	2
Total stockholders' equity	2	2
Common Stock
Stockholders' equity:
Common stock	102	97
Total stockholders' equity	$ 102	$ 97